Pacific Biosciences of California, Inc. (PACB) Analysts See $-0.17 EPS; Ciena (CIEN) Sellers Increased By 5.19% Their Shorts

Pacific Biosciences of California, Inc. (NASDAQ:PACB) Logo

Analysts expect Pacific Biosciences of California, Inc. (NASDAQ:PACB) to report $-0.17 EPS on May, 1.They anticipate $0.03 EPS change or 15.00% from last quarter’s $-0.2 EPS. After having $-0.21 EPS previously, Pacific Biosciences of California, Inc.’s analysts see -19.05% EPS growth. It closed at $7.32 lastly. It is down 211.86% since April 17, 2018 and is uptrending. It has outperformed by 207.49% the S&P500. Some Historical PACB News: 02/05/2018 – Pacific Biosciences 1Q Loss/Shr 20c; 07/03/2018 Pacific Biosciences Enhances Performance and Affordability of Key Applications on the Sequel System; 13/03/2018 – PACIFIC BIOSCIENCES GETS U.S. PATENT FOR CONCATEMER SEQUENCING; 15/03/2018 – Study Demonstrates Potential for SMRT Sequencing to Improve the Safety of Gene Therapy Protocols; 22/03/2018 – Pacific Biosciences Prevails in Patent Eligibility Ruling Against Oxford Nanopore; 08/05/2018 – Pacific Biosciences Settles Patent Suit With Oxford Nanopore; 13/03/2018 – Pacific Biosciences Announces Issuance of U.S. Patent for Concatemer Sequencing; 22/03/2018 – Pacific Biosciences: Court Denies Motion by Oxford Nanopore to Dismiss Complaint; 08/05/2018 – PACIFIC BIOSCIENCES OF CALIFORNIA – AS PER OUTCOME, OXFORD NANOPORE WILL REFRAIN FROM OFFERING “2D” SEQUENCING PRODUCTS THROUGH END OF 2023 IN UK & GERMANY; 11/04/2018 – HudsonAlpha Using PacBio Sequencing for Childhood Developmental Disabilities Research

Ciena Corporation (NYSE:CIEN) had an increase of 5.19% in short interest. CIEN’s SI was 5.68 million shares in April as released by FINRA. Its up 5.19% from 5.40 million shares previously. With 1.74 million avg volume, 3 days are for Ciena Corporation (NYSE:CIEN)’s short sellers to cover CIEN’s short positions. The stock decreased 0.81% or $0.32 during the last trading session, reaching $38.38. About 1.75 million shares traded. Ciena Corporation (NYSE:CIEN) has risen 83.53% since April 17, 2018 and is uptrending. It has outperformed by 79.16% the S&P500. Some Historical CIEN News: 31/05/2018 – CIENA CORP CIEN.N – AROUND THE ANNOUNCEMENTS WITH ZTE, l DON’T THINK THAT HAS REALLY BEEN AT ALL IMPACTFUL TO US -CEO, CONF CALL; 15/05/2018 – GLOBENET IN PACT WITH CIENA FOR LATAM SUBMARINE NETWORK; 31/05/2018 – CIENA: INTENT TO BUY PACKET DESIGN; 26/04/2018 – CIENA COMMENTS IN E-MAIL TO BLOOMBERG NEWS; 31/05/2018 – CIENA 2Q REV. $730.0M, EST. $726.4M; 13/03/2018 – SMTC Appoints Steve Waszak as Chief Financial Officer; 06/03/2018 – Ciena Cites $476.9 Million in Additional Tax Expense From Tax Bill for 1Q Loss; 19/04/2018 – DJ Ciena Corporation, Inst Holders, 1Q 2018 (CIEN); 06/03/2018 – Ciena 1Q Loss/Shr $3.29; 05/03/2018 Ciena FYQ1 On Tap: Street Looks to Cloud, 5G To Bolster Soft Telco Environment — Barron’s Blog

More recent Ciena Corporation (NYSE:CIEN) news were published by: which released: “Report: Developing Opportunities within Amazon, Walmart, Extreme Networks, Ciena, Nova Measuring Instruments, and Maiden — Future Expectations, Projections Moving into 2019 – GlobeNewswire” on April 15, 2019. Also published the news titled: “28 Stocks Moving In Tuesday’s Pre-Market Session – Benzinga” on March 26, 2019.‘s news article titled: “CIENA (CIEN) Management NDR Shows Acacia (ACIA) Concerns Are Overdone – JPMorgan –” with publication date: March 22, 2019 was also an interesting one.

Investors sentiment decreased to 1.16 in 2018 Q4. Its down 0.18, from 1.34 in 2018Q3. It dropped, as 34 investors sold Ciena Corporation shares while 102 reduced holdings. 72 funds opened positions while 86 raised stakes. 139.52 million shares or 4.53% less from 146.14 million shares in 2018Q3 were reported. Alliancebernstein Limited Partnership holds 2.84M shares or 0.07% of its portfolio. Cornerstone Advsrs invested 0% of its portfolio in Ciena Corporation (NYSE:CIEN). Metropolitan Life Ins Company Ny reported 82,049 shares. Winslow Evans & Crocker reported 26,800 shares or 0.31% of all its holdings. Commerzbank Aktiengesellschaft Fi has invested 0.02% in Ciena Corporation (NYSE:CIEN). Victory Capital Mgmt Incorporated invested in 0.08% or 976,966 shares. Moreover, Eqis Mgmt has 0.1% invested in Ciena Corporation (NYSE:CIEN). Piedmont Investment Advsrs holds 6,249 shares. Howe And Rusling Inc holds 0% or 45 shares in its portfolio. Raymond James Assocs accumulated 106,894 shares or 0.01% of the stock. Retail Bank Of Montreal Can has invested 0.01% in Ciena Corporation (NYSE:CIEN). Essex Com Limited Com has 1.2% invested in Ciena Corporation (NYSE:CIEN) for 225,568 shares. California-based Shelton Mgmt has invested 0.02% in Ciena Corporation (NYSE:CIEN). State Of Wisconsin Board, a Wisconsin-based fund reported 311,000 shares. Prudential has invested 0.01% in Ciena Corporation (NYSE:CIEN).

Among 16 analysts covering Ciena (NYSE:CIEN), 10 have Buy rating, 0 Sell and 6 Hold. Therefore 63% are positive. Ciena had 22 analyst reports since October 23, 2018 according to SRatingsIntel. Needham downgraded the shares of CIEN in report on Tuesday, November 20 to “Hold” rating. The stock of Ciena Corporation (NYSE:CIEN) earned “Buy” rating by Jefferies on Tuesday, January 22. The stock has “Hold” rating by Deutsche Bank on Wednesday, March 6. Raymond James maintained it with “Outperform” rating and $41 target in Friday, December 14 report. The rating was maintained by FBR Capital on Wednesday, March 6 with “Buy”. The stock of Ciena Corporation (NYSE:CIEN) has “Buy” rating given on Wednesday, March 6 by Cowen & Co. The stock of Ciena Corporation (NYSE:CIEN) earned “Neutral” rating by Bank of America on Wednesday, January 30. The stock of Ciena Corporation (NYSE:CIEN) has “Buy” rating given on Wednesday, March 6 by Argus Research. Nomura maintained the shares of CIEN in report on Friday, December 14 with “Buy” rating. The firm has “Buy” rating given on Tuesday, November 20 by M Partners.

Ciena Corporation provides equipment, software, and services that support the transport, switching, aggregation, service delivery, and management of voice, video, and data traffic on communications networks worldwide. The company has market cap of $5.99 billion. The companyÂ’s Networking Platforms segment offers hardware networking solutions optimized for the convergence of coherent optical transport, optical transport network switching, and packet switching. It has a 37.93 P/E ratio. The Company’s products include 6500 Packet-Optical Platform and the 5430 Reconfigurable Switching System, Waveserver stackable interconnect system, CoreDirector Multiservice Optical Switches, and OTN configuration for the 5410 Reconfigurable Switching System, as well as Z-Series Packet-Optical Platform; 3000 family of service delivery switches and service aggregation switches, and the 5000 family of service aggregation switches, as well as 8700 Packetwave Platform and the Ethernet packet configuration for the 5410 Service Aggregation Switch; and 4200 Advanced Services Platform, Corestream 5100/5200 Advanced Services Platform, Common Photonic Layer, and 6100 Multiservice Optical Platform.

Since October 18, 2018, it had 0 buys, and 25 selling transactions for $3.59 million activity. $310,348 worth of Ciena Corporation (NYSE:CIEN) was sold by SMITH GARY B on Thursday, December 27. 1,963 shares valued at $65,465 were sold by MOYLAN JAMES E JR on Wednesday, November 14. 1,000 shares were sold by McFeely Scott, worth $34,292 on Monday, December 17. Rothenstein David M had sold 2,000 shares worth $77,382. HAMILTON RICK also sold $149,483 worth of Ciena Corporation (NYSE:CIEN) shares. $68,569 worth of Ciena Corporation (NYSE:CIEN) was sold by FRODSHAM JAMES on Monday, December 17. $85,741 worth of Ciena Corporation (NYSE:CIEN) shares were sold by ALEXANDER STEPHEN B.

Pacific Biosciences of California, Inc. designs, develops, and makes sequencing systems to resolve genetically complex problems. The company has market cap of $1.11 billion. The companyÂ’s single molecule real-time sequencing technology enables single molecule real-time detection of biological processes. It currently has negative earnings. It offers PacBio RS II and Sequel Systems that conducts, monitors, and analyzes biochemical sequencing reactions.

Since November 27, 2018, it had 0 buys, and 1 insider sale for $188,500 activity. ORDONEZ KATHY sold 25,000 shares worth $188,500.

Among 3 analysts covering Pacific Biosciences (NASDAQ:PACB), 0 have Buy rating, 0 Sell and 3 Hold. Therefore 0 are positive. Pacific Biosciences had 5 analyst reports since October 19, 2018 according to SRatingsIntel. The firm has “Neutral” rating given on Monday, November 12 by Cantor Fitzgerald. The rating was downgraded by Stephens to “Equal-Weight” on Tuesday, April 2. The firm has “Market Perform” rating given on Friday, January 4 by Cowen & Co.

Pacific Biosciences of California, Inc. (NASDAQ:PACB) Institutional Positions Chart